FindTrial
Sign In

Prospective Study of Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma after Nephroureterectomy

Prospective Study of Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma after Nephroureterectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17010367
Enrollment
Unknown
Registered
2017-01-09
Start date
2017-01-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Tract Urothelial Carcinoma

Interventions

Control:observation
Adjvant chemotherapy:Platinum-based drugs adjvant chemotherapy

Sponsors

Deparetment of Urology, Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Unilateral UTUC; Surgery is nephroureterectomy; Patholgy was urothelial carcinoma and stage more than T2; Inclusion should follow all above conditions.

Exclusion criteria

Exclusion criteria: Preoperatively receiving neoadjuvant chemotherapy; Concomitant with bladder cancer; Previous urothelial carcinoma history; Previous cancer history.

Design outcomes

Primary

MeasureTime frame
No-turmor progression survival;disease specific survival;overall survival;—

Secondary

MeasureTime frame
chemotherapy finishing rate;renal insufficiency rate;renal dialysis ratio within five years;chemotherapy side effects;—

Countries

China

Contacts

Public ContactDong Wei

Deparetment of Urology, Beijing Hospital

dongwei63@hotmail.com+86 010 85136271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026